Bone Biologics Corporation is a clinical-stage developer of orthobiologic products for spine fusion markets. The Company is focused on bone regeneration in lumbar spinal fusion using neural epidermal growth factor-like 1 protein (NELL-1) in combination with demineralized bone matrix (DBM), a demineralized bone matrix from the Musculoskeletal Transplant Foundation (MTF) Biologics. The combination NELL-1/DBM medical device is an osteopromotive recombinant protein that provides target specific control over bone regeneration. NELL-1 in combination with DBM. NELL-1, a proprietary skeletal-specific growth factor that is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
公司代碼BBLG
公司名稱Bone Biologics Corp
上市日期Nov 27, 2015
CEOFrelick (Jeffrey)
員工數量2
證券類型Ordinary Share
年結日Nov 27
公司地址2 Burlington Woods Dr Ste 100
城市BURLINGTON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編01803-4551
電話17815524452
網址https://www.bonebiologics.com/
公司代碼BBLG
上市日期Nov 27, 2015
CEOFrelick (Jeffrey)